Clinical characteristics, management, and prognosis of pembrolizumab-induced hypophysitis: retrospective analysis based on case reports - Report - MDSpire
Advertisement
Clinical characteristics, management, and prognosis of pembrolizumab-induced hypophysitis: retrospective analysis based on case reports
Clinical Report: Analysis of Clinical Features of Pembrolizumab-Induced Hypophysitis
Overview
This retrospective review summarizes the clinical characteristics, management, and outcomes of hypophysitis associated with pembrolizumab. Key findings indicate a high incidence of fatigue and adrenal insufficiency.
Background
Pembrolizumab-induced hypophysitis is a rare but significant immune-related adverse event that can lead to serious endocrine complications.
Data Highlights
Characteristic
Value
Median Age
66 years
Median Time to Onset
15 weeks
Fatigue
86.4%
Nausea/Vomiting
54.5%
Adrenal Insufficiency
40.9%
Hormone Replacement Therapy
81.8%
Clinical Improvement
90.9%
Persistent Endocrine Dysfunction
95.5%
Key Findings
Pembrolizumab-induced hypophysitis typically presents with nonspecific symptoms such as fatigue and nausea.
Median cortisol and ACTH levels were significantly reduced in affected patients.
Normal pituitary MRI findings were observed in 50% of cases.
Hormone replacement therapy was administered in 81.8% of cases, leading to clinical improvement in 90.9% of patients.
Persistent endocrine dysfunction was noted in 95.5% of patients despite treatment.
Rechallenge with pembrolizumab did not result in recurrence of hypophysitis in most cases.
Clinical Implications
Early recognition of pembrolizumab-induced hypophysitis is critical for timely management and prevention of complications. Clinicians should maintain a high index of suspicion for endocrine dysfunction in patients receiving pembrolizumab, particularly those presenting with fatigue and gastrointestinal symptoms.
Conclusion
Pembrolizumab-induced hypophysitis is characterized by a high incidence of persistent endocrine dysfunction.
